Island Pharmaceuticals Ltd has released a press release.
Dosing complete in ISLA-101 SAD study
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
In the deck
Earlier from Island Pharmaceuticals
- Quarterly Activity Report and Appendix 4C
- Third cohort dosed in ISLA-101 Single Ascending Dose study
- Approval to commence dosing 3rd cohort of ISLA-101 SAD study
- R&D Tax Incentive loan facility secured with Radium Capital
- Second cohort dosed in ISLA-101 Single Ascending Dose study
Later from Island Pharmaceuticals
- Island investor presentation
- $1.95million Fully Underwritten Rights Issue
- Prospectus
- Island Pharmaceuticals to raise $1.95 million for ISLA-101 development
- Security Class Suspension from Quotation ILAO
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals